Bewtra Meenakshi, Lewis James D
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Med Clin North Am. 2010 Jan;94(1):93-113. doi: 10.1016/j.mcna.2009.08.015.
This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients.
本文描述了常用炎症性肠病（IBD）药物的癌症风险，重点是血液系统恶性肿瘤风险。免疫抑制疗法在IBD治疗中的使用日益增加，使这个问题变得更加重要。由于疾病严重程度不同以及同时使用其他免疫抑制药物，评估这些药物的研究变得复杂。必须权衡所有疗法的潜在风险与这些疗法能为这些患者带来的益处。
